Zydus Lifesciences Ltd

Zydus Lifesciences Ltd maintains a strong liquidity position, with a current ratio of 1.89, indicating that the company has sufficient current assets to cover its current liabilities. The company's liquidity is supported by a free cash flow of INR 35,155,000,000, which provides flexibility for reinvestment or debt reduction. However, the company's net cash position is negative after subtracting total debt, which introduces a medium liquidity risk. In terms of profitability, Zydus Lifesciences Ltd demonstrates a return on equity (ROE) of 18.89% and a return on assets (ROA) of 12.16%, both of which are strong indicators of efficient capital utilization and asset management. These metrics suggest that the company is generating solid returns for its shareholders and effectively deploying its assets to generate profit. The company's operating income of INR 57,597,000,000 and net income of INR 45,255,000,000 further support its profitability. Zydus Lifesciences Ltd operates primarily in the pharmaceuticals segment, with a focus on prescription and over-the-counter drugs. The company's revenue is concentrated in this segment, with no significant geographic diversification disclosed in the available data. This concentration may expose the company to risks associated with regulatory changes or market shifts in the pharmaceutical industry. The company's growth trajectory is supported by a strong revenue base of INR 232,415,000,000 and a gross profit of INR 160,103,000,000. While specific growth projections for the next fiscal year are not provided, the company's capital expenditure of INR -17,126,000,000 suggests a focus on maintaining and optimizing existing operations rather than aggressive expansion. Zydus Lifesciences Ltd faces a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio of 0.13 indicates a conservative capital structure, with a relatively low proportion of debt compared to equity. The risk assessment also notes that the company has a low potential for dilution, which is supported by the fact that the number of shares outstanding has not changed between basic and diluted shares. Recent events and disclosures indicate that Zydus Lifesciences Ltd is maintaining a stable financial position. Analysts have provided a mean price target of INR 1,001.96 and a median price target of INR 975.00, with a mean recommendation of 2.79, which is slightly above the "buy" threshold. The company has received a mix of strong-buy, buy, and hold recommendations, suggesting a generally positive outlook among analysts.